Top Markets
#1 Black Phoenix Black Phoenix +166.09%
#2 Islamic Coin Islamic Coin +158.29%
#3 Glidr Glidr +58.56%
#4 DOVU DOVU +20.73%
#5 Cryptopia Cryptopia +20.42%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.03%
#7 MarsCoin MarsCoin +10.05%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +9.23%
#9 Pons Pons +8.66%
#10 stake.link stake.link +8.27%
Coin of the day
Black Phoenix Black Phoenix
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Sienna Biopharmaceuticals, Inc. Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals, Inc.

SNNAQ
Kedudukan dalam Saham #42234
Sienna Biopharmaceuticals, Inc. was a clinical-stage biopharmaceutical firm... Sienna Biopharmaceuticals, Inc. was a clinical-stage biopharmaceutical firm dedicated to discovering and advancing pharmaceutical treatments across diverse therapeutic fields. Its primary focus involved crafting therapies within immunology and inflammation, specifically targeting particular tissue pathways, notably in the skin. Among its pipeline, SNA-120 stood out as a pioneering, first-in-class inhibitor of tropomyosin receptor kinase A, undergoing Phase IIb clinical evaluation for addressing psoriasis and its associated itching. Another key candidate, SNA-125, a topical dual Janus kinase 3 inhibitor, progressed through Phase I/II clinical studies for conditions like atopic dermatitis, psoriasis, and pruritus. Furthermore, Sienna was advancing SNA-001, a topical suspension incorporating silver particles, into pivotal clinical trials not only for acne treatment but also for diminishing light-colored hair, encompassing shades such as white, gray, blonde, light brown, and light red. Established in 2010 and based in Westlake Village, California, the company originally operated as Sienna Labs, Inc. before rebranding as Sienna Biopharmaceuticals, Inc. in February 2016. However, the firm faced significant financial challenges, initiating Chapter 11 bankruptcy proceedings on September 16, 2019, which subsequently converted to Chapter 7 liquidation on December 18, 2019.
Harga Saham
$0.0001
Disegerakkan terakhir: 2026-08-11
Modal Pasaran
$3.09K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Sienna Biopharmaceuticals, Inc. (SNNAQ)

Kategori

Healthcare
Pendapatan untuk Sienna Biopharmaceuticals, Inc. (SNNAQ)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Sienna Biopharmaceuticals, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Sienna Biopharmaceuticals, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR